Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
MLX 337 sought your views on proposals to restrict the availability of medicines containing pseudoephedrine and ephedrine by a change to legal status from pharmacy availability (P) to prescription only (POM), together with a restriction in pack size. These proposals were made in response to reports of misuse of these substances in the manufacture of the Class A controlled drug methylamphetamine (commonly known as "crystal meth"). This consultation followed the release of the International Narcotics Control Board Report 2006 on 1 March 2007 (external link).
Publication of additional information - 4 May 2007
In light of external interest and questions on these proposals, the MHRA made available more details on the information relating to this consultation exercise (please see link below). To give interested parties a chance to consider this additional information the deadline for comments was extended from 1 June 2007 to 29 June 2007.
›
Public consultation (MLX 337): Proposals to restrict the availability of medicines containing pseudephedrine and ephedrine - addtional information
Outcome of consultation exercise MLX 337 - 29 August 2007
The following table broadly indicates how pharmaceutical bodies, medical bodies, and others responded to the consultation. The minutes of the Commission on Human Medicines (CHM) discussion of the outcome of this consultation are also available:
›
Minutes of Commission on Human Medicines discussion of outcome of consultation on reclassification of pseudoephedrine from P to POM
| Medical Colleges, Clinicians and other medical/professional bodies |
|---|
|
Yes to reclassification |
|
No comment
|
|
No definitive views on reclassification but issues raised
|
|
No to reclassification
|
| Industry and Trade Associations |
|---|
|
Yes to reclassification |
|
No to reclassification |
| Patient Groups, Consumer Groups and Members of Public |
|---|
|
Yes to reclassification |
|
No definitive views on reclassification but issues raised
|
|
No to reclassification
|
| Enforcement Agencies |
|---|
|
Yes to reclassification |
|
No definitive views on reclassification - summary of intelligence picture presented |
|
No to reclassification |
Download documents:
-
Minutes of Commission on Human Medicines discussion of outcome of consultation on reclassification of pseudoephedrine from P to POM (60Kb)
-
Public consultation (MLX 337): Proposals to restrict the availability of medicines containing pseudoephedrine and ephedrine by a change to legal status from pharmacy to prescription only together with a restriction in pack size - additional letter (59Kb)
-
Public consultation (MLX 337): Proposals to restrict the availability of medicines containing pseudoephedrine and ephedrine by a change to legal status from pharmacy (P) to prescription only (POM) together with a restriction in pack size (118Kb)
